I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.2
SGD
Market Closed
Market Cap:
S$191.9m
Relative Value
The Relative Value of one 42C stock under the Base Case scenario is hidden SGD. Compared to the current market price of 0.2 SGD, IX Biopharma Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
42C Relative Value
HIDDEN
Multiples Across Competitors
42C Competitors Multiples
IX Biopharma Ltd Competitors
IX Biopharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SG |
I
|
IX Biopharma Ltd
SGX:42C
|
191.6m SGD | 26.5 | -32.2 | -39.3 | -33.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.9B USD | 15.1 | 47.8 | 32.2 | 34.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
596.5B USD | 6.3 | 22.3 | 15.4 | 19 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
283.9B CHF | 4.6 | 30.3 | 12.8 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
247.6B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.1B GBP | 5.5 | 31.4 | 17.4 | 24.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.9B USD | 4.7 | 16.8 | 10.4 | 12.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.9B USD | 2.5 | 20.2 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
